No Data
No Data
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $62
Express News | Bristol-Myers Squibb Company : Barclays Cuts to Underweight From Equal-Weight
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
Pfizer Stock Gains After Raising Annual Outlook
Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Pricing Concerns
USA pharmaceutical stocks 'switching trading': two weight-loss giants fall, while stagnant giants rise in turn.
The rotation of this stock price is not only due to momentum effects, but also because the USA pharmaceutical industry seems to have responded well to the regulatory pressure brought by the Inflation Reduction Act.
103189865 : mony half widrow
103159190 : Why is McDonald's earnings forecast lower than expected and the pre-market price will rise?
104371487 On Paris : Thanks you
105535782 : ok
Captain Woon 103159190 : Market is irrational… buy on bad news
View more comments...